New targeted therapies for treatment of thrombosis in antiphospholipid syndrome

Expert Reviews in Molecular Medicine

Volumn 9, Issue 30, 2007, Pages 1-15

  Pierangeli, Silvia S ^a   Vega Ostertag, Mariano E ^b   González, Emilio B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Instituto Fares Taie   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E RECEPTOR 2; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5 LEIDEN; CD20 ANTIBODY; CYTOTOXIC AGENT; DILAZEP; DIPYRIDAMOLE; ENOXAPARIN; ESTROGEN; FLUINDOSTATIN; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTHROMBIN; RECEPTOR; RITUXIMAB; THROMBOPLASTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BLEEDING; CELL FUNCTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG TARGETING; GENE EXPRESSION REGULATION; HORMONE SUBSTITUTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORBIDITY; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERMINAL DISEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOGENICITY; THROMBOPHILIA; THROMBOSIS; UPREGULATION;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD PLATELETS; COMPLEMENT ACTIVATION; ENDOTHELIAL CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MONOCYTES; PROTHROMBIN; THROMBOSIS;

ANIMALIA;

EID: 36348973956     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399407000506     Document Type: Review

References (104)

1. Harris, E.N. (1987) Syndrome of the black swan. Br J Rheumatol 26, 324-326
2. Wilson, W.A. et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 42, 1309-1311
3. 2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87, 4120-4124
4. Atsumi, T. and Koike, T. (2002) Clinical relevance of antiprothrombin antibodies. Autoimmun Rev 1, 49-53
5. 2glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 56, 1638-1647
6. Chen, X.X. et al. (2007) Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice J Immunol 178, 5351-5356
7. Cesarman-Maus, G. et al. (2006) Autoantibodies against the fibrinolytic receptor, annexin A2, in antiphospholipid syndrome. Blood 107, 4375-7382
8. Boey, M.L. et al. (1983) Thrombosis in SLE: Striking associations with the presence of circulating lupus anticoagulant. Br Med J 287, 101-102
9. Ginsburg, K.S. et al. (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis, Ann Intern Med 117, 997-1002
10. McClain, M.T. et al. (2004) The prevalence, onset and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 50, 1226-1232
11. Moroni, G. et al. (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43, 28-36
12. Moroni, G. et al. (2005) The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 45, 903-911
13. Miyakis, S. et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4, 295-306
14. Gleason, C.B. et al. (1993) A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin negative systemic lupus erythematosus. Am Heart J 125, 1123-1129
15. Toubi, E. et al. (2005) Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 23, 499-504
16. Atsumi, T. et al. (2005) Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 14, 499-504
17. Levine, S.R. et al. (2000) Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 51, 169-185
18. Sherer, Y. et al. (2002) Transverse myelitis in patients with antiphospholipid antibodies - the importance of early diagnosis and treatment. Clin Rheumatol 21, 207-210
19. Al-Matar, M., Jaimes, J. and Malleson, P. (2000) Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics 2, 107-108
20. Hughes, G.R. (2003) Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 79, 81-83
21. Mesa, H.A. et al. (1993) Sneddon's syndrome and phospholipid antibodies. Clin Rheumatol 12, 253-256
22. Shoenfeld, Y. et al. (2004) Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 31, 1344-1348
23. Asherson, R.A. (2005) Multiorgan failure and antiphospholipid antibodies: The catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 210, 727-733
24. Wiedermann, F.J. (2006) Alveolar and serum antiphospholipid antibodies in acute respiratory distress syndrome associated with catastrophic antiphospholipid syndrome. Ann Rheum Dis 65, 413
25. Asherson, R.A. and Cervera, R. (2003) Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 1, 61-78
26. Nzerue, C.M. et al. (2002) "Black swan in the kidney": Renal involvement in the antiphospholipid antibody syndrome. Kidney 62, 733-744
27. Tektonidou, M.G. et al. (2003) Asyptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: A prospective study by magnetic resonance imaging. Arthritis Rheum 48, 732-736
28. Khamashta, M.A. et al. (1995) The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 332, 993-997
29. Krnic-Barrie, S. et al. (1997) A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med 157, 2101-2108
30. Crowther, M.A. et al. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349, 1133-1138
31. Finazzi, G. et al. (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3, 848-853
32. Garcia, D.A., Khamashta, M.A. and Crowther, M.A. (2007) How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: A case-based review. Blood [Epub ahead of print]
33. Erkan, D. et al. (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41, 924-929
34. Erkan, D. et al. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 56, 2382-2391
35. Rubenstein, E. et al. (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33, 355-357
36. Branch, D.W. et al. (1990) Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: A model for autoimmune fetal loss. Am J Obstet Gynecol 163, 210-216
37. Blank, M. et al. (1991) Induction of antiphospholipid syndrome in naïve mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 88, 3069-3073
38. Pierangeli, S.S. et al. (1999) Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99, 1997-2000
39. 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 101, 157-162
40. Roubey, R.A.S. (1998) Mechanisms of autoantibody-mediated thrombosis. Lupus 7, S114-119
41. Holers, V.M. et al. (2002) C3 activation is required for anti-phospholipid antibody-induced fetal loss. J Exp Med 195, 211-220
42. Salmon, J.E., Girardi, G. and Holers, V.M. (2002) Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 61, 46-50
43. Pierangeli, S.S. et al. (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52, 2120-2124
44. 2 glycoprotein I is complement-dependent and requires a priming factor. Blood 106, 2340-2346
45. Khamashta, M.A. et al. (1988) Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 47, 849-854
46. Campbell, A.L. et al. (1995) Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 73, 529-534
47. Espinola, R.G. et al. (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87, 518-522
48. Edwards, M.H. et al. (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96, 4380-4384
49. Martinuzzo, M.E. et al. (1993) Antiphospholipid Antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 70, 667-671
50. 2glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 79, 42-45
51. 2glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the Antiphospholipid syndrome. J Rheumatol 25, 51-56
52. 2glycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J Rheumatol 30, 55-59
53. Vega-Ostertag, M., Harris, E.N. and Pierangeli, S.S. (2004) Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 50, 2911-2919
54. 2glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 278, 33831-33838
55. 2glycoprotein I antibodies in complex with β2 glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib/IX-V. Arthritis Rheum 54, 2558-2567
56. Simantov, E. et al. (1995) Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96, 2211-2219
57. Pierangeli, S.S. et al. (2001) Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 88, 245-250
58. Espinola, R.G. et al. (2002) E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 1, 843-848
59. Kaplanski, G. et al. (2000) Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis. Arthritis Rheum 43, 55-64
60. Nemerson, Y. (1988) Tissue factor and hemostasis. Blood 71, 1-8
61. Semerato, N. and Colucci, M. (1997) Tissue factor in health and disease. Thromb Haemost 78, 759-764
62. Kornberg, A. et al. (1994) Induction of tissue factor-like activity in monocyes by anti-cardiolipin antibodies. J Immunol 153, 1328-1332
63. Cuadrado, M.J. et al. (1997) Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum 40, 834-841
64. Amengual, O. et al. (1998) The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79, 276-281
65. Dobado-Barrios, M. (1999) Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 82, 1578-1582
66. Martini, F. et al. (1996) Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 5, 206-211
67. Reverter, J.C. (1998) Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 41, 1420-1427
68. Forastiero, R.R., Martinuzzo, M.E. and De Larranaga, G. (2005) Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus 14, 129-136
69. Zhou, H., Wolberg, A.S. and Roubey, R.A. (2004) Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104, 2353-2358
70. Cuadrado, M.J. et al. (2006) Vascular endotelial growth factor expresión in monocytes from patients with primary antiphospholipid síndrome. J Thromb Haemost 4, 2461-2469
71. Williams, F.M. et al. (2000) Systemic endothelial cell markers in primary antiphospholipid syndrome. J Thromb Haemost 84, 742-746
72. Xie, H., Ray, P.E. and Short, B.L. (2005) NF-kappa B activation plays a role in superoxide-mediated cerebral endothelial dysfunction after hypoxia/reoxygenation. Stroke 36, 1047-1052
73. Morgan, E.N. et al. (2003) Nuclear factor kappa B mediates a procoagulant response in monocytes during extracorporeal circulation. J Thorac Cardiovasc Surg 125, 165-171
74. Chen, F. et al. (1999) New insights into the role of nuclear factor-κB, aubiquitous transcription factor in the initiation of diseases. Clin Chem 45, 7-17
75. Saccani, S., Pantano, S. and Natoli, G. (2002) p38-dependent marking of inflammatory genes for increasing NF-kappa B recruitment. Nat Immunol 3, 69-75
76. Firestein, G.S. (2004) NF-κB: Holy grail for rheumatoid arthritis. Arthritis Rheum 50, 2381-2386
77. Cohen, P. (1997) The search for physiological substrates ofMAPand SAP kinases in mammalian cells. Trends Cell Biol 7, 353-358
78. McGilvray, I.D. et al. (2002) Monocyte adhesion and transmigration induce tissue-factor expression: Role of the mitogen-activated protein kinases. Shock 18, 51-57
79. 2glycoprotein I antibodies. Thromb Haemost 88, 851-857
80. 2glycoprotein I antibodies. Int Immunol 16, 1632-1641
81. Vega-Ostertag, M. et al. (2005) Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 52, 1545-1554
82. López-Pedrera, C. et al. (2006) Antiphopholipid antibodies from patients with the antiphospholipid syndrome induce tissue factor expression through the simultaneous activation of NF-KappaB/Rel proteins via p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 54, 301-311
83. Simoncini, S. et al. (2004) Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 17, 489-500
84. Vega-Ostertag, M.E. et al. (2007) Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 5, 1828-1834
85. Montiel-Manzano, G. et al. (2007) In vivo effects of an inhibitor of nuclear factor-kappa (κ) B on thrombogenic properties of Antiphospholipid antibodies. Ann NY Acad Sci 1108, 540-553
86. 2glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44, 2870-2878
87. Ferrara, D.E. et al. (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 48, 3272-3279
88. Ferrara, D.E. et al. (2004) Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2, 1558-1563
89. 2glycoprotein I to phospholipids based on its crystal structure. EMBO J 18, 5166-5174
90. 2glycoprotein I ameliorates thrombosis induced by antiphospholipid antibodies in mice. Arthritis Rheum 54 (suppl), S559 (Abstract)
91. 2glycoprotein I antibodies. J Immunol 160, 5572-5578
92. 2glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 15, 358-365
93. 2glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem 275, 15541-15548
94. 2Glycoprotein I antibodies. Blood 105, 1964-1969
95. Akira, S., Takeda, K. and Kaisho, T. (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2, 675-680
96. Raschi, E. et al. (2003) Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101, 3495-3500
97. Pierangeli, S.S. et al. (2007) Toll like receptor 4 is involved in Antiphospholipid-mediated thrombosis: In vivo studies. Ann Rheum Dis [Epub ahead of print]
98. Pierangeli, S.S. et al. (1995) Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 74, 1361-1367
99. Sammaritano, L.R. et al. (1997) Anticardiolipin IgG subclasses: association with IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 40, 1998-2006
100. Romay-Penabad, Z. et al. (2007) C5a receptor-deficient micer are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann NY Acad Sci 1108, 554-566
101. Munakata, Y. et al. (2000) Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 83, 728-731
102. Carbone, J. et al. (1999) Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 8, 274-278
103. Davis, W.D. and Brey, R.L. (1992) Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol 10, 455-460
104. Potti, A. et al. (2006) Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 107, 1391-1396